11/11
How do patients with #ATTRCM die?

New insights from Kevin Alexander, MD and Masri Ahmad, MD #ATTRibuteCM at #HeartFailure2025

#CardioSky #MedSky #Cardiology

10/11
Marianna Fontana presents new data at #HeartFailure2025 from #ATTRibuteCM

Exploring effects of acoramidis on functional capacity & QOL in patients with variant ATTR-CM.

6-minute walking distance - 87m (!) mean increase

KCCQ health status gain - 20pt (!) mean increase

#CardioSky #MedSky

9/11
More from #ATTRibuteCM

In variant #ATTRCM, acoramidis led to a reduction in the composite of ACM/CVH, ACM and CVH.

These clinical benefits were accompanied by halting in the rise in NT-proBNP levels, suggesting underlying disease-modifying effects.

#CardioSky #MedSky #Cardiology

8/11
New data from #ATTRibuteCM presented at #HeartFailure2025

Intriguing analysis by Kevin Alexander, MD. High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM

#CardioSky #MedSky #Cardiology